Skip to main content
GutCited

Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.

Ashwin N Ananthakrishnan, Chengwei Luo, Vijay Yajnik, Hamed Khalili, John J Garber et al.
Other Cell host & microbe 2017 399 citations

Study Design

Study Type
Observational Study
Population
CD or UC patients starting vedolizumab
Intervention
Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.
Primary Outcome
Week 14 remission prediction by microbiome
Effect Direction
Mixed
Risk of Bias
Moderate

Abstract

The gut microbiome plays a central role in inflammatory bowel diseases (IBDs) pathogenesis and propagation. To determine whether the gut microbiome may predict responses to IBD therapy, we conducted a prospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integrin therapy (vedolizumab). Disease activity and stool metagenomes at baseline, and weeks 14, 30, and 54 after therapy initiation were assessed. Community α-diversity was significantly higher, and Roseburia inulinivorans and a Burkholderiales species were more abundant at baseline among CD patients achieving week 14 remission. Several significant associations were identified with microbial function; 13 pathways including branched chain amino acid synthesis were significantly enriched in baseline samples from CD patients achieving remission. A neural network algorithm, vedoNet, incorporating microbiome and clinical data, provided highest classifying power for clinical remission. We hypothesize that the trajectory of early microbiome changes may be a marker of response to IBD treatment.

TL;DR

It is hypothesized that the trajectory of early microbiome changes may be a marker of response to IBD treatment, and a neural network algorithm, vedoNet, incorporating microbiome and clinical data, provided highest classifying power for clinical remission.

Used In Evidence Reviews

Similar Papers

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.